CeGaT GmbH’s Post

Cancer profiling is a pivotal tool in oncology research, enabling scientists to understand the complex molecular mechanisms of cancer. These insights help, for example, to stratify patients for the best treatment or to identify patients eligible for clinical trials.  With our TSO500 products, you get a comprehensive genomic profiling of your tumor samples. Learn more here: https://lnkd.in/e4JEKuPG #genetics #sequencing #TSO500 #oncology #research #cancerresearch #tumorprofiling

💊 A new in vivo model for Melanoma 🔬 Get access to a novel ectopic/orthotopic model that recapitulates genetic drivers found in a significant proportion of human melanoma: ▶️ YUMM1.7 ◀️ This syngeneic model is now available for evaluating your new therapies. Learn more information here: https://buff.ly/3WZqGoq #melanoma #oncology #research #model #preclinical "immunooncology

good to hear

Read article: https://lnkd.in/gqGV3RfT Oncology research is the foundation of the fight against cancer. Here's how genetic profiling can improve early detection, monitoring, and the development of novel therapeutics for various cancers. Dive into the advancements in #gene expression profiling and see how these technologies tackle challenges and drive breakthroughs in oncology. Read the full article! #CancerResearch #Oncology #LifeSciences

📹 In this exclusive interview from UROonco24, Dr. Juan Gómez Rivas and Dr. Ursula Vogl discuss advancements in genomic profiling and the use of PARP inhibitors in treating metastatic prostate cancer, with a focus on genomic profiling, patient selection and toxicity management. Dr. Vogl highlights the importance of testing both somatic and germline mutations to ensure patients receive the best treatment. She shares her expert opinion on PARP inhibitors and how to manage toxicities with careful monitoring and adjustments, stressing the need for personalised treatment approaches. 👇 #prostatecancer #oncology

🧬 Gain Clarity on Your patient's Breast #Cancer Journey with #siParadigm's PROSIGNA. 🧬Prosigna is a second-generation genomic test that utilizes the renowned PAM50 gene signature to identify the intrinsic subtype of your patients' breast cancer. Visit www.siparadigm.com today to discover more about how Prosigna #oncology #innovation

This week, we’re at the @ColdSpring Harbor Laboratory conference on Mechanisms and Models of Cancer, presenting our preclinical work on therapeutic strategies to overcome KRASG12C inhibitor resistance in highly aggressive genetic subtypes of lung adenocarcinoma. This includes our work with Kymera Therapeutics showing the potential of #STAT3 degradation to offer a novel, targeted approach. #DrugDiscovery #Oncology #TPD

Journey through a patient's mCRPC treatment program with urologist Neal Shore. Updated with recent data, in this animated video you'll hear about the importance of genetic testing when treating prostate cancer with PARP inhibitor monotherapy. The video is designed to make learning simple and engaging. You will learn about: > Efficacy and safety profiles of PARP inhibitors for prostate cancer > The role of genetic testing and how to use it to assess HRRm status and influence treatment decision-making > Data from key PARPi mCRPC studies and the clinical implication of this data 👉https://ow.ly/rTCX50QABXL ZERO Prostate Cancer endorsed #MedEd #MedicalEducation #Oncology #ProstateCancer

Journey through a patient's mCRPC treatment program with urologist Neal Shore. Updated with recent data, in this animated video you'll hear about the importance of genetic testing when treating prostate cancer with PARP inhibitor monotherapy. The video is designed to make learning simple and engaging. You will learn about: > Efficacy and safety profiles of PARP inhibitors for prostate cancer > The role of genetic testing and how to use it to assess HRRm status and influence treatment decision-making > Data from key PARPi mCRPC studies and the clinical implication of this data 👉https://ow.ly/rTCX50QABXL ZERO Prostate Cancer endorsed #MedEd #MedicalEducation #Oncology #prostatecancer

GenVivo is excited to be attending #AACR this week. Come by Wednesday April 10th from 9:00 AM-12:30 PM to meet our team Victor Constantinescu, Robert G. Johnson, Makoto Sato, Alexander Cunha and check out our posters! 7250 - Serial assessment of GEN2, a retroviral vector for gene transfer of an optimized thymidine kinase and GM-CSF, for genomic integration into peripheral blood mononuclear cells (PBMCs) in a Phase 1 clinical trial in adult patients with solid tumors 7254 - Evaluation of scFv and diabody pseudotyped Sindbis engineered retrovectors for targeted cancer therapy